GLP-1 Agonists

GLP-1 Agonists
Accession Number
DBCAT002693  (DBCAT003437, DBCAT003869, DBCAT004144)

Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes.

DrugDrug Description
ExenatideA GLP-1 agonist used in the management of type 2 diabetes mellitus.
LiraglutideA GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes.
AlbiglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
TaspoglutideTaspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted...
LixisenatideA GLP-1 receptor agonist used for the management of type 2 diabetes mellitus.
SemaglutideA glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus.
TirzepatideA dual GIP and GLP-1 receptor agonist being investigated for the treatment of type II diabetes.
Drugs & Drug Targets
ExenatideGlucagon-like peptide 1 receptortarget
ExenatideSerum albumincarrier
ExenatideDipeptidyl peptidase 4enzyme
LiraglutideGlucagon-like peptide 1 receptortarget
LiraglutideDipeptidyl peptidase 4enzyme
LiraglutideSerum albumincarrier
AlbiglutideGlucagon-like peptide 1 receptortarget
DulaglutideGlucagon-like peptide 1 receptortarget
LixisenatideGlucagon-like peptide 1 receptortarget
SemaglutideSerum albumincarrier
SemaglutideDipeptidyl peptidase 4enzyme
SemaglutideGlucagon-like peptide 1 receptortarget
SemaglutideLipoprotein lipaseenzyme
SemaglutideAlpha-amylase 1enzyme
TirzepatideGlucagon-like peptide 1 receptortarget
TirzepatideGastric inhibitory polypeptidetarget
TirzepatideSerum albumincarrier